نتائج البحث - Agnès Guerci‐Bresler

تنقيح النتائج
  1. 1
    Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

    Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes حسب Mikkael A. Sekeres, Hagop M. Kantarjian, Pierre Fenaux, Pamela S. Becker, Adam Boruchov, Agnès Guerci‐Bresler, Kuolung Hu, Janet Franklin, Yow‐Ming Wang, Dietmar Berger

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

    Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation حسب Jean‐Claude Chomel, Marie Laure Bonnet, Nathalie Sorel, Ivan Sloma, Annelise Bennaceur‐Griscelli, Delphine Réa, Laurence Legros, Anne Marfaing‐Koka, Jean Bourhis, Shanti Amé, Agnès Guerci‐Bresler, Philippe Rousselot, Ali G. Turhan

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

    Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome حسب Marc Berger, Bruno Pereira, Philippe Rousselot, Pascale Cony‐Makhoul, Martine Gardembas, Laurence Legros, Martine Escoffre‐Barbe, Franck‐Emmanuel Nicolini, Sandrine Saugues, Céline Lambert, Delphine Réa, Agnès Guerci‐Bresler, Stéphane Giraudier, Joëlle Guilhot, Susanne Saußele, François‐Xavier Mahon

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia حسب Laurence Legros, Franck E. Nicolini, Gabriel Étienne, Philippe Rousselot, Delphine Réa, Stéphane Giraudier, Agnès Guerci‐Bresler, Françoise Huguet, Martine Gardembas, Martine Escoffre, Jean‐Christophe Ianotto, Marie‐Pierre Noël, Bruno Varet, Thomas Pagliardini, Isabelle Touitou, Stéphane Morisset, François‐Xavier Mahon

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome

    Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome حسب Mariane de Montalembert, Jean-Antoine Ribeil, Valentine Brousse, Agnès Guerci‐Bresler, Aspasia Stamatoullas, Jean-Pierre Vannier, C. Dumesnil, Agnès Lahary, Mohamed Touati, Krimo Bouabdallah, Marina Cavazzana, Emmanuelle Chauzit, Amandine Baptiste, Thibaud Lefèbvre, Hervé Puy, Caroline Elie, Zoubida Karim, Olivier Ernst, Christian Rosé

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

    Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study حسب Maël Heiblig, Delphine Réa, Marie‐Lorraine Chrétien, Aude Charbonnier, Philippe Rousselot, Valérie Coiteux, Martine Escoffre‐Barbe, Viviane Dubruille, Françoise Huguet, Émilie Cayssials, Éric Hermet, Agnès Guerci‐Bresler, Shanti Amé, Lucila Sackmann‐Sala, Lydia Roy, Mohamad Sobh, Stéphane Morisset, Gabriel Étienne, Franck E. Nicolini

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

    Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up... حسب Jorge E. Cortés, Hagop M. Kantarjian, Delphine Réa, Meir Wetzler, Jeffrey H. Lipton, Luke P. Akard, H. Jean Khoury, Mauricette Michallet, Agnès Guerci‐Bresler, Charles Chuah, Andrzej Hellmann, Raghunadharao Digumarti, Purvish M. Parikh, Laurence Legros, Krzysztof Warzocha, Michele Baccarani, Elizabeth Li, Mihaela Munteanu, Franck E. Nicolini

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations

    Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations حسب Sarah Ducamp, Caroline Kannengiesser, Mohamed Touati, Loïc Garçon, Agnès Guerci‐Bresler, Jean François Guichard, Christiane Vermylen, Joaquim Dochir, Hélène A. Poirel, Fanny Fouyssac, L Mansuy, Geneviève Leroux, G. Tertian, Robert Girot, H. Heimpel, Thomas Matthes, Neila Talbi, Jean‐Charles Deybach, Carole Beaumont, Hervé Puy, Bernard Grandchamp

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

    Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study حسب Delphine Réa, Guylaine Henry, Zena Khaznadar, Gabriel Étienne, François Guilhot, Franck E. Nicolini, Joëlle Guilhot, Philippe Rousselot, Françoise Huguet, Laurence Legros, Martine Gardembas, Viviane Dubruille, Agnès Guerci‐Bresler, Aude Charbonnier, Frédéric Maloisel, Jean‐Christophe Ianotto, Bruno Villemagne, François‐Xavier Mahon, Hélène Moins‐Teisserenc, Nicolas Dulphy, Antoine Toubert

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

    Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study حسب Delphine Réa, Franck E. Nicolini, Michel Tulliez, François Guilhot, Joëlle Guilhot, Agnès Guerci‐Bresler, Martine Gardembas, Valérie Coiteux, Gaëlle Guillerm, Laurence Legros, Gabriel Étienne, Jean‐Michel Pignon, Bruno Villemagne, Martine Escoffre‐Barbe, Jean‐Christophe Ianotto, Aude Charbonnier, Hyacinthe Johnson‐Ansah, Marie‐Pierre Noël, Philippe Rousselot, François‐Xavier Mahon

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group حسب Delphine Réa, Shanti Amé, Marc Berger, Jean‐Michel Cayuela, Aude Charbonnier, Valérie Coiteux, Pascale Cony‐Makhoul, Viviane Dubruille, Stéphanie Dulucq, Gabriel Étienne, Laurence Legros, Franck E. Nicolini, Catherine Roche‐Lestienne, Martine Escoffre‐Barbe, Martine Gardembas, Agnès Guerci‐Bresler, Hyacinthe Johnson‐Ansah, Françoise Rigal‐Huguet, Philippe Rousselot, François‐Xavier Mahon

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

    Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia حسب Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini, Agnès Guerci‐Bresler, Françoise Rigal‐Huguet, Frédéric Maloisel, Valérie Coiteux, Martine Gardembas, Christian Berthou, Anne Vekhoff, Delphine Réa, Éric Jourdan, Christian Allard, Alain Delmer, Philippe Rousselot, Laurence Legros, Marc Berger, Sélim Corm, Gabriel Étienne, Catherine Roche‐Lestienne, Virginie Éclache, François‐Xavier Mahon, François Guilhot

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

    Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib... حسب Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Philippe Agapé, Franck E. Nicolini, Bruno Varet, Martine Gardembas, Gabriel Étienne, Delphine Réa, Lydia Roy, Martine Escoffre‐Barbe, Agnès Guerci‐Bresler, Michel Tulliez, Stéphane Prost, Marc Spentchian, Jean Michel Cayuela, Josy Reiffers, Jean‐Claude Chomel, Ali G. Turhan, Joëlle Guilhot, François Guilhot, François‐Xavier Mahon

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q حسب Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne‐Rauzy, Ghulam Mufti, Moshe Mittelman, Petra Muus, Peter te Boekhorst, Guillermo Sanz, Consuelo del Cañizo, Agnès Guerci‐Bresler, Lars Nilsson, Uwe Platzbecker, Michael Lübbert, Bruno Quesnel, Mario Cazzola, Arnold Ganser, David Bowen, Brigitte Schlegelberger, Carlo Aul, Robert Knight, John Francis, Tommy Fu, Eva Hellström‐Lindberg

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

    Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes حسب Frédérik Damm, Olivier Kosmider, Véronique Gelsi‐Boyer, Aline Renneville, Nadine Carbuccia, Claire Hidalgo-Curtis, Véronique Della Valle, Lucile Couronné, Laurianne Scourzic, Virginie Chesnais, Agnès Guerci‐Bresler, Bohrane Slama, Odile Beyne‐Rauzy, Aline Schmidt, Aspasia Stamatoullas‐Bastard, François Dreyfus, Thomas Prébet, Stéphane de Botton, Norbert Vey, Michael Morgan, Nicholas C.P. Cross, Claude Preudhomme, Daniel Birnbaum, Olivier Bernard, Michaëla Fontenay

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Validation of the revised international prognostic scoring system (<scp>IPSS</scp>‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet <scp>MDS</scp> (<scp>EUMDS</scp>) registry

    Validation of the revised international prognostic scoring system (<scp>IPSS</scp>‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European... حسب Louise de Swart, Alex Smith, W. Thomas Johnston, Detlef Haase, Jackie Droste, Pierre Fenaux, Argiris Symeonidis, Guillermo Sanz, Eva Hellström‐Lindberg, Jaroslav Čermák, Ulrich Germing, Reinhard Stauder, Otilia Georgescu, Marius MacKenzie, Luca Malcovati, Mette Skov Holm, António Almeida, Krzysztof Mądry, Borhane Slama, Agnès Guerci‐Bresler, Laurence Sanhès, Odile Beyne‐Rauzy, Elisa Luño, David Bowen, Théo de Witte

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

    Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study حسب Reinhard Stauder, Ge Yu, Karin A. Koinig, Timothy Bagguley, Pierre Fenaux, Argiris Symeonidis, Guillermo Sanz, Jaroslav Čermák, Moshe Mittelman, Eva Hellström‐Lindberg, Saskia Langemeijer, Mette Skov Holm, Krzysztof Mądry, Luca Malcovati, Aurelia Tatic, Ulrich Germing, Aleksandar Savić, Corine van Marrewijk, Agnès Guerci‐Bresler, Elisa Luño, Jackie Droste, Fabio Efficace, Alexandra Smith, David Bowen, Théo de Witte

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders

    BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders حسب Frédérik Damm, Virginie Chesnais, Yasunobu Nagata, Kenichi Yoshida, Laurianne Scourzic, Yusuke Okuno, Raphaël Itzykson, Masashi Sanada, Yuichi Shiraishi, Véronique Gelsi‐Boyer, Aline Renneville, Satoru Miyano, Hiraku Mori, Lee‐Yung Shih, Sophie Park, François Dreyfus, Agnès Guerci‐Bresler, Éric Solary, Christian Rosé, Stéphane Chèze, Thomas Prébet, Norbert Vey, Marion Legentil, Yannis Duffourd, Stéphane de Botton, Claude Preudhomme, Daniel Birnbaum, Olivier Bernard, Seishi Ogawa, Michaëla Fontenay, Olivier Kosmider

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

    Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes حسب Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, Pierre Fenaux, Argiris Symeonidis, Jaroslav Čermák, Eva Hellström‐Lindberg, Reinhard Stauder, Guillermo Sanz, Moshe Mittelman, Mette Skov Holm, Luca Malcovati, Krzysztof Mądry, Ulrich Germing, Aurelia Tatic, Aleksandar Savić, António Almeida, Njetočka Gredelj-Šimec, Agnès Guerci‐Bresler, Odile Beyne‐Rauzy, Dominic Culligan, Ιoannis Kotsianidis, Raphaël Itzykson, Corine van Marrewijk, Nicole M. A. Blijlevens, David Bowen, Théo de Witte

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

    Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients حسب Franck E. Nicolini, Stéphanie Dulucq, Lisa Boureau, Pascale Cony‐Makhoul, Aude Charbonnier, Martine Escoffre‐Barbe, Françoise Rigal‐Huguet, Valérie Coiteux, Bruno Varet, Viviane Dubruille, Pascal Lenain, Philippe Rousselot, Delphine Réa, Agnès Guerci‐Bresler, Laurence Legros, Jixing Liu, Martine Gardembas, Jean‐Christophe Ianotto, Pascal Turlure, Hyacinthe Johnson‐Ansah, Juliana Martiniuc, Henry Jardel, Bertrand Joly, Patricia Zunic, Tawfiq Henni, Bruno Villemagne, Marc Berger, Émilie Cayssials, François Guilhot, Fabrice Larosa, Joëlle Guilhot, Gabriel Étienne, François‐Xavier Mahon

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: